SISVEL-INTERNATIONAL
19.7.2022 09:32:08 CEST | Business Wire | Press release
Sisvel International S.A. (“Sisvel”) today announced the launch of a patent pool on Wi-Fi 6 technology. The initial members of this pool will be Huawei, Mediatek, Philips, SK Telecom and Wilus. Huawei and Philips are also the first licensees of the pool. Along with the Wi-Fi 6 pool, Sisvel also debuted a new structured payment plan — the Licensing Incentive Framework for Technologies (LIFT).
Even before the official publication of the standard by IEEE, Wi-Fi 6 (802.11ax) has been pervasive in the market. Increased average throughput per user -the standard itself talks about a fourfold increase- and increased number of concurrent users in high density scenarios (offices, campuses, airports, stadiums, etc.) are among the main benefits of Wi-Fi 6 when compared to Wi-Fi 5. Wi-Fi 6 has brought wireless connectivity to a whole new level. Additional information about the technological advances of Wi-Fi 6 and how it enhances and enables existing and new applications can be found on Sisvel’s blog [https://www.sisvel.com/blog/wireless-communications ].
Sisvel is committed to create licensing solutions that work for both innovators and implementers. To facilitate early adoption of licenses, Sisvel created a new royalty scheme, the Licensing Incentive Framework for Technologies (or LIFT), which will be available to licensees of this new pool. “LIFT is the result of a two-year effort, specifically built to address the disadvantage that sometimes early licensees can feel and the “I don’t want to be the first” syndrome,” reveals Mattia Fogliacco, President of Sisvel International. “We are confident that LIFT will substantially help in fostering the creation of a level playing field,” he continues. Further information on LIFT can be found on Sisvel’s website [https://www.sisvel.com/licensing-programs/wireless-communications/wifi6/patent-pool/license-terms ] and blog [https://www.sisvel.com/blog/wireless-communications/lift-levelling-the-playing-field-for-early-licensees ].
“The patent pool will increase transparency of patent licensing and reduce licensing disputes in the field. Implementers can obtain a license under all patents in the pool at one time, which increases licensing efficiency and reduces licensing costs,” comments Alan Fan, Head of Huawei’s Intellectual Property Rights Department.
Steven Liu, Director at MediaTek states: “We support industry-driven licensing solutions that help to promote the adoption of new standards. We believe this group of industry participants, and with Sisvel as experienced administrator, can work together toward such goal.”
“Patent pools are the most efficient and transparent way to license Standard Essential Patents, reducing transaction costs and stimulating a level-playing field. For many years, Sisvel has been one of our partners in licensing audio/video codecs, and we are happy that we can now further expand our relationship into the Wi-Fi domain,” says Jako Eleveld, Head of IP Licensing at Royal Philips.
“SK Telecom is committed to always find the most efficient way to license its patents. We believe that this pool combines key patent owners, high quality assets and an innovative royalty scheme to align the interests of patent owners and implementors,” declares Hogeun Kim, Vice President of Corporate Legal Office at SK Telecom.
Wilus’ CEO, Jin Sam Kwak, explains that “Wilus endorses LIFT, the alternative scheme for sponsoring the adoption of this new technology for implementers. Adjusting royalty payments based on the global market penetration of Wi-Fi 6 licenses can incentivize adoption. With LIFT, the Wi-Fi 6 pool is made more attractive to potential licensees.”
Sisvel’s Wi-Fi Program Manager, Andrea Rombolà adds that “Licensing Wi-Fi technology has never been easy, but innovation has to be rewarded, because this is the only way to generate a virtuous circle to incentivize parties to innovate. Wi-Fi is such a key technology to our lives today, made ever so much more important by the pandemic and the associated work-from-home phenomena. This new pool represents a very efficient way to clear the rights of major owners of Wi-Fi 6 standard essential patents.” Mattia Fogliacco continues: “During the past two years of facilitation, we have created a framework that we feel will benefit the Markets for Technology as a whole, removing friction and aligning interests of innovators and implementers. We trust that this, together with the quality of the IP contributed by the participating patent owners, will quickly attract additional licensees and possibly additional patent owners.”
Sisvel is making the valuable portfolios included in the pool accessible on fair, reasonable, and non-discriminatory terms and conditions, by offering a royalty-bearing, non-transferable, non-assignable, non-exclusive license, with no right to grant sublicenses, under the participating patent owners’ patent portfolios essential to the 802.11ax specification.
Further information about the terms and conditions of this license offer is available on Sisvel’s website [https://www.sisvel.com/licensing-programs/wireless-communications/wifi6/patent-pool/introduction ]. For more details you may contact Sisvel at the following e-mail address WiFi6-Licensing@sisvel.com .
About Sisvel
Sisvel International S.A. is the holding company of the Sisvel Group. Sisvel is a world leader in fostering innovation and managing IP. The group identifies, evaluates and maximises the value of IP assets for its partners around the world, providing firms with a revenue stream which can be reinvested in innovation for the generation of future revenues. Sisvel has more than 40 years’ experience in the management of successful patent portfolios, including those relating to audio compression standards (MP3 and MPEG audio), as well as broadcasting and digital terrestrial television standards maintained by the Digital Video Broadcasting Project. Sisvel operates patent pools and joint licensing programmes in the fields of mobile communication, wireless local area networking 802.11, video coding, digital video broadcasting, recommendation engines and broadband access to data networks.
www.sisvel.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005183/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
